Gateway Advisory LLC Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Gateway Advisory LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.9% during the second quarter, HoldingsChannel reports. The institutional investor owned 2,978 shares of the company’s stock after purchasing an additional 138 shares during the period. Gateway Advisory LLC’s holdings in Johnson & Johnson were worth $419,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Trust Asset Management LLC purchased a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $1,041,000. YHB Investment Advisors Inc. grew its holdings in shares of Johnson & Johnson by 1.4% during the second quarter. YHB Investment Advisors Inc. now owns 78,981 shares of the company’s stock valued at $11,107,000 after buying an additional 1,121 shares during the last quarter. Ropes Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson by 7.0% during the second quarter. Ropes Wealth Advisors LLC now owns 60,604 shares of the company’s stock valued at $8,523,000 after buying an additional 3,970 shares during the last quarter. American Institute for Advanced Investment Management LLP grew its holdings in shares of Johnson & Johnson by 1.8% during the second quarter. American Institute for Advanced Investment Management LLP now owns 7,052 shares of the company’s stock valued at $992,000 after buying an additional 125 shares during the last quarter. Finally, Hunter Perkins Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $14,286,000. Hedge funds and other institutional investors own 68.44% of the company’s stock.

Several equities research analysts recently issued reports on the stock. Credit Suisse Group restated a “buy” rating and issued a $161.00 target price on shares of Johnson & Johnson in a report on Tuesday, April 28th. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 target price on the stock. in a report on Tuesday, July 7th. Citigroup raised their target price on shares of Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Argus restated a “buy” rating and issued a $155.00 target price (down previously from $165.00) on shares of Johnson & Johnson in a report on Friday, March 27th. Finally, Barclays raised their target price on shares of Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and twelve have given a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Buy” and an average price target of $163.38.

Shares of JNJ stock opened at $150.01 on Thursday. The company has a market capitalization of $394.50 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 3.32 and a beta of 0.69. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The company’s fifty day moving average price is $143.94 and its 200-day moving average price is $144.00. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.31 and a quick ratio of 1.05.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Thursday, July 16th. The company reported $1.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.17. The firm had revenue of $18.34 billion for the quarter, compared to the consensus estimate of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.70%. The company’s revenue was down 10.8% on a year-over-year basis. During the same period last year, the firm earned $2.58 EPS. Equities research analysts expect that Johnson & Johnson will post 7.85 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a dividend of $1.01 per share. The ex-dividend date of this dividend is Monday, August 24th. This represents a $4.04 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s payout ratio is 46.54%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Basic Economics

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.